Annual Total Expenses
$33.32 M
+$6.75 M+25.42%
30 September 2022
Summary:
NeuBase Therapeutics annual total expenses is currently $33.32 million, with the most recent change of +$6.75 million (+25.42%) on 30 September 2022. During the last 3 years, it has risen by +$6.75 million (+25.42%).NBSE Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Expenses
$1.59 M
-$2.10 M-56.87%
30 September 2023
Summary:
NeuBase Therapeutics quarterly total expenses is currently $1.59 million, with the most recent change of -$2.10 million (-56.87%) on 30 September 2023.NBSE Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBSE Total Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | - |
| 3 y3 years | +25.4% | -77.8% |
| 5 y5 years | +30.6% | -92.9% |
NBSE Total Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | ||||
| 5 y | 5 years | ||||
| alltime | all time | at high | -92.9% |
NeuBase Therapeutics Total Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2023 | - | $1.59 M(-56.9%) |
| June 2023 | - | $3.69 M(-11.3%) |
| Mar 2023 | - | $4.16 M(+5.3%) |
| Dec 2022 | - | $3.95 M(-48.9%) |
| Sept 2022 | $33.32 M(+25.4%) | $7.72 M(-7.6%) |
| June 2022 | - | $8.36 M(-15.8%) |
| Mar 2022 | - | $9.93 M(+35.9%) |
| Dec 2021 | - | $7.30 M(+1.9%) |
| Sept 2021 | $26.57 M(+55.6%) | $7.17 M(-18.9%) |
| June 2021 | - | $8.84 M(+49.9%) |
| Mar 2021 | - | $5.90 M(+26.5%) |
| Dec 2020 | - | $4.66 M(-8.7%) |
| Sept 2020 | $17.07 M(-33.1%) | $5.11 M(+33.6%) |
| June 2020 | - | $3.82 M(-12.2%) |
| Mar 2020 | - | $4.36 M(+15.1%) |
| Dec 2019 | - | $3.78 M(-83.0%) |
| Sept 2019 | $25.51 M(+181.0%) | $22.31 M(+1862.7%) |
| June 2019 | - | $1.14 M(-1.4%) |
| Mar 2019 | - | $1.15 M(+27.2%) |
| Dec 2018 | - | $906.40 K(-14.3%) |
| Sept 2018 | $9.08 M(-61.9%) | $1.06 M(-9.3%) |
| June 2018 | - | $1.17 M(-19.2%) |
| Mar 2018 | - | $1.44 M(-65.5%) |
| Dec 2017 | - | $4.18 M(-20.5%) |
| Sept 2017 | $23.85 M(-5.8%) | $5.26 M(+33.9%) |
| June 2017 | - | $3.93 M(-48.9%) |
| Mar 2017 | - | $7.69 M(+10.2%) |
| Dec 2016 | - | $6.98 M(+2.4%) |
| Sept 2016 | $25.31 M(+44.9%) | $6.81 M(-10.4%) |
| June 2016 | - | $7.60 M(+4.0%) |
| Mar 2016 | - | $7.31 M(+103.4%) |
| Dec 2015 | - | $3.59 M(+3.9%) |
| Sept 2015 | $17.47 M(+91.5%) | $3.46 M(+3.7%) |
| June 2015 | - | $3.33 M(-51.0%) |
| Mar 2015 | - | $6.81 M(+73.4%) |
| Dec 2014 | - | $3.92 M(+27.5%) |
| Sept 2014 | $9.12 M(+97.4%) | $3.08 M(+49.8%) |
| June 2014 | - | $2.06 M(+4.4%) |
| Mar 2014 | - | $1.97 M(-2.6%) |
| Dec 2013 | - | $2.02 M(+12.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2013 | $4.62 M(+40.6%) | $1.80 M(+35.0%) |
| June 2013 | - | $1.34 M(+99.9%) |
| Mar 2013 | - | $668.10 K(-18.0%) |
| Dec 2012 | - | $814.80 K(-34.7%) |
| Sept 2012 | $3.29 M(+164.3%) | $1.25 M(+96.5%) |
| June 2012 | - | $634.70 K(-30.1%) |
| Mar 2012 | - | $907.50 K(+82.5%) |
| Dec 2011 | - | $497.20 K(+32.4%) |
| Sept 2011 | $1.24 M(+22.4%) | $375.60 K(+24.6%) |
| June 2011 | - | $301.50 K(+39.6%) |
| Mar 2011 | - | $215.90 K(-38.4%) |
| Dec 2010 | - | $350.30 K(+6.6%) |
| Sept 2010 | $1.02 M(+8.9%) | $328.60 K(-7.3%) |
| June 2010 | - | $354.60 K(+104.0%) |
| Mar 2010 | - | $173.80 K(+9.7%) |
| Dec 2009 | - | $158.50 K(-24.1%) |
| Sept 2009 | $932.90 K(+39.9%) | $208.80 K(-3.6%) |
| June 2009 | - | $216.60 K(-50.8%) |
| Mar 2009 | - | $440.40 K(+563.3%) |
| Dec 2008 | - | $66.40 K(-78.8%) |
| Sept 2008 | $666.60 K(>+9900.0%) | $312.60 K(+2132.9%) |
| June 2008 | - | $14.00 K(-85.4%) |
| Mar 2008 | - | $96.00 K(-60.5%) |
| Dec 2007 | - | $243.00 K(>+9900.0%) |
| Sept 2007 | $0.00(0.0%) | $0.00(0.0%) |
| June 2007 | - | $0.00(-100.0%) |
| Mar 2007 | - | $1.75 M(>+9900.0%) |
| Dec 2006 | $0.00(-100.0%) | $0.00(0.0%) |
| Sept 2006 | - | $0.00(-100.0%) |
| June 2006 | - | -$26.70 K(-98.2%) |
| Mar 2006 | - | -$1.47 M(-73.6%) |
| Dec 2005 | -$5.56 M(+41.7%) | -$5.56 M(+288.5%) |
| Sept 2005 | - | -$1.43 M(+1.3%) |
| June 2005 | - | -$1.41 M(+14.1%) |
| Mar 2005 | - | -$1.24 M(+4.8%) |
| Dec 2004 | -$3.92 M(+50.9%) | -$1.18 M(+26.0%) |
| Sept 2004 | - | -$937.40 K(+1.3%) |
| June 2004 | - | -$925.10 K(+5.3%) |
| Mar 2004 | - | -$878.30 K |
| Dec 2003 | -$2.60 M | - |
FAQ
- What is NeuBase Therapeutics annual total expenses?
- What is the all time high annual total expenses for NeuBase Therapeutics?
- What is NeuBase Therapeutics quarterly total expenses?
- What is the all time high quarterly total expenses for NeuBase Therapeutics?
What is NeuBase Therapeutics annual total expenses?
The current annual total expenses of NBSE is $33.32 M
What is the all time high annual total expenses for NeuBase Therapeutics?
NeuBase Therapeutics all-time high annual total expenses is $33.32 M
What is NeuBase Therapeutics quarterly total expenses?
The current quarterly total expenses of NBSE is $1.59 M
What is the all time high quarterly total expenses for NeuBase Therapeutics?
NeuBase Therapeutics all-time high quarterly total expenses is $22.31 M